Spots Global Cancer Trial Database for Individual Patient Compassionate Use of Mirdametinib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Individual Patient Compassionate Use of Mirdametinib
Official Title:
Study ID: NCT05028166
Interventions
Mirdametinib (MEK Inhibitor)
Study Description
Brief Summary: This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Detailed Description:
Eligibility
Minimum Age: 2 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
